Shares of HCW Biologics Inc. experienced a dramatic surge on Friday, closing at $1.22, a 262% increase from the previous session. The rally was fueled by the company's first-quarter financial results, which swung to a profit driven by a licensing agreement with Beijing Trimmune Biotech. Despite the sharp rise, the stock slipped to $1.01 in after-hours trading, and the company continues to grapple with significant financial and regulatory challenges.
The clinical-stage biotechnology firm reported Q1 revenue of $6.54 million and net income of $3.47 million, a stark contrast to the $5,065 in revenue and a $2.2 million loss recorded in the same period last year. The turnaround was largely attributed to a $6.5 million licensing payment from Beijing Trimmune Biotech, which was recognized in March upon closing an exclusive global license agreement for HCW11-006. The payment was made in cash and an equity stake in Trimmune, underscoring the deal's non-operational nature.
Despite the one-time profit, HCW Biologics' underlying financial health remains precarious. The company reported just $1.23 million in cash as of March 31, against current liabilities of $19.96 million and short-term debt of $6.58 million. It has accumulated $102.3 million in net losses since inception and has yet to generate revenue from its own commercial products. The company's most recent filing retained a going-concern warning, highlighting doubts about its ability to fund operations over the next year.
HCW Biologics also faces a pressing threat of delisting from the Nasdaq. The company is scheduled to present its case before a Nasdaq panel on May 5, seeking to overturn a staff decision to delist its stock for failing to maintain a minimum bid price of $1.00. While Friday's surge briefly pushed the stock above that threshold, the listing issue remains unresolved. To address this, management has asked shareholders to approve a reverse stock split at the annual meeting on June 15, with a ratio ranging from one-for-five to one-for-twenty.
On the clinical front, HCW Biologics is advancing its pipeline. The company expects to release early Phase 1 data for HCW9302, a treatment for alopecia areata, in the first half of 2026. CEO Dr. Hing C. Wong expressed confidence in the drug's profile, citing preclinical data that showed prolonged activity in the body at low doses. However, the alopecia market is already competitive, with approved oral JAK inhibitors from Eli Lilly (Olumiant), Pfizer (Litfulo), and Sun Pharma (Leqselvi) available to patients in the U.S.
In addition, HCW Biologics announced that its fusion immunotherapy candidate, HCW11-040, demonstrated efficacy in preventing bronchopulmonary dysplasia in an animal model. The company plans to complete enabling studies for an Investigational New Drug application in the second half of 2027. Bronchopulmonary dysplasia, which affects 10,000 to 15,000 premature infants annually in the U.S., currently has no approved treatments.
Short-term liquidity pressures also weigh on the company. HCW obtained an extension until May 26 to pay the remaining $620,000 of a settlement with contract manufacturer EirGenix. It also owes $750,000 for legal fees from Cooley, due by August 31 unless it secures at least $4 million in financing before then. The company's financial strain is evident, with a heavy reliance on external funding to sustain operations.
Investor sentiment remains cautious. HCW Biologics has been viewed as a recovery play, with the recent profit spike offering a temporary boost. The real test lies in whether the company can convert this momentum into sustained capital, advance its clinical programs, and retain its Nasdaq listing. Upcoming deadlines and the reverse stock split vote will be critical milestones for the biotech.
